Abstract: Disclosed are methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, disorder of bile acid homeostasis, or organ fibrosis, which includes administering to a subject a therapeutically effective amount of a pharmaceutical composition containing an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.

Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

Abstract: Aklavinone C-11 hydroxylase separated from Streptomyces sp.; a gene encoding same; an expression vector comprising said gene; a microorganism transformed with said vector; and a process for preparing novel hybrid anthracyclines by using said vector.